Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACST

Acasti Pharma (ACST) Stock Price, News & Analysis

Acasti Pharma logo

About Acasti Pharma Stock (NASDAQ:ACST)

Key Stats

Today's Range
$3.03
$3.14
50-Day Range
$2.56
$3.60
52-Week Range
$1.98
$3.60
Volume
12,261 shs
Average Volume
22,722 shs
Market Capitalization
$29.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACST Stock News Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
Craig-Hallum Sticks to Their Buy Rating for Acasti Pharma (ACST)
See More Headlines

ACST Stock Analysis - Frequently Asked Questions

Acasti Pharma Inc. (NASDAQ:ACST) announced its earnings results on Friday, June, 21st. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.30.

Acasti Pharma shares reverse split before market open on Monday, July 10th 2023.The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acasti Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
6/21/2024
Today
10/17/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACST
CIK
1444192
Employees
32
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.44)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.85 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-13.61%
Return on Assets
-11.56%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.86
Quick Ratio
7.86

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.57 per share
Price / Book
0.47

Miscellaneous

Outstanding Shares
9,399,000
Free Float
8,770,000
Market Cap
$29.23 million
Optionable
Not Optionable
Beta
1.52
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ACST) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners